Osiris Therapeutics Stock Price, News & Analysis (OTCMKTS:OSIR)

$8.99 +0.11 (+1.24 %)
(As of 02/20/2018 02:26 PM ET)
Previous Close$8.88
Today's Range$8.70 - $8.99
52-Week Range$2.67 - $8.99
Volume9,483 shs
Average Volume37,903 shs
Market Capitalization$306.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.12

About Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics logoOsiris Therapeutics, Inc. is a cellular and regenerative medicine company. The Company is focused on researching, developing and marketing products in the wound, orthopedic, and sports medicine markets. The Company operates through Biosurgery business segment, which focuses on products for wound care, orthopedics, and sports medicine to harness the ability of cells and novel constructs to promote the body's natural healing. The Company's products include Grafix, Stravix, TruSkin, Cartiform and BIO4. The Company produces and distributes Grafix for acute and chronic wounds; Stravix for tendon repair; TruSkin for wound closure; Cartiform, a viable cartilage mesh for cartilage repair, and BIO4 for bone growth. The Company's BioSmart cryopreservation process retains the native characteristics and inherent functionality of tissue. Its BioSmart process includes preservation of the three dimensional (3D) matrix, endogenous growth factors, and tissue-resident cells.

Receive OSIR News and Ratings via Email

Sign-up to receive the latest news and ratings for OSIR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryBiotechnology
SectorMedical
SymbolOTCMKTS:OSIR
CUSIP68827R10
Phone443-545-1800

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares34,530,000

Osiris Therapeutics (OTCMKTS:OSIR) Frequently Asked Questions

What is Osiris Therapeutics' stock symbol?

Osiris Therapeutics trades on the OTCMKTS under the ticker symbol "OSIR."

Who are some of Osiris Therapeutics' key competitors?

Who are Osiris Therapeutics' key executives?

Osiris Therapeutics' management team includes the folowing people:

  • Peter Friedli, Chairman of the Board (Age 62)
  • Jason Keefer, Interim President, Chief Executive Officer (Age 45)
  • Linda Palczuk, President, Chief Executive Officer (Age 55)
  • Linda L. Chang, Chief Financial Officer (Age 51)
  • Frank D. Czworka Jr., Vice President, General Manager of Wound Care (Age 46)
  • Adrian P. Mollo, General Counsel (Age 41)
  • Alla N. Danilkovitch Ph.D., Chief Scientific Officer (Age 51)
  • Thomas M. Brandt Jr., Independent Director (Age 63)
  • Thomas J. Knapp, Independent Director (Age 63)
  • Willi Miesch, Independent Director

How do I buy Osiris Therapeutics stock?

Shares of Osiris Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Osiris Therapeutics' stock price today?

One share of Osiris Therapeutics stock can currently be purchased for approximately $8.99.

How big of a company is Osiris Therapeutics?

Osiris Therapeutics has a market capitalization of $306.59 million.

How can I contact Osiris Therapeutics?

Osiris Therapeutics' mailing address is 7015 ALBERT EINSTEIN DRIVE, COLUMBIA MD, 21046. The biotechnology company can be reached via phone at 443-545-1800 or via email at [email protected]


MarketBeat Community Rating for Osiris Therapeutics (OSIR)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  133 (Vote Underperform)
Total Votes:  205
MarketBeat's community ratings are surveys of what our community members think about Osiris Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Osiris Therapeutics (OTCMKTS:OSIR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Osiris Therapeutics (OTCMKTS:OSIR) Consensus Price Target History

Price Target History for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS:OSIR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/16/2016Brean CapitalReiterated RatingSell$4.00View Rating Details
(Data available from 2/20/2016 forward)

Earnings

Osiris Therapeutics (OTCMKTS:OSIR) Earnings History and Estimates Chart

Earnings by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2015Q315$0.06($0.02)$25.40 million$24.30 millionViewN/AView Earnings Details
8/5/2015Q215$0.06$0.03$23.60 million$23.70 millionViewN/AView Earnings Details
5/8/2015Q115$0.04$18.40 million$21.00 millionViewN/AView Earnings Details
3/5/2015Q414$0.05$0.03$18.53 million$19.50 millionViewN/AView Earnings Details
11/7/2014Q314($0.01)$0.02$14.80 million$17.20 millionViewN/AView Earnings Details
8/7/2014Q214$0.16($0.04)$11.00 million$13.30 millionViewN/AView Earnings Details
5/12/2014($0.08)($0.02)$9.00 million$10.05 millionViewN/AView Earnings Details
3/5/2014Q413$0.65$0.11$7.50 million$8.10 millionViewN/AView Earnings Details
11/1/2013Q313($0.10)($0.05)$6.70 million$6.88 millionViewN/AView Earnings Details
8/5/2013Q2 2013($0.09)($0.11)$4.35 million$5.29 millionViewN/AView Earnings Details
5/7/2013Q1 2013($0.09)($0.08)$3.53 million$4.06 millionViewN/AView Earnings Details
3/6/2013Q4 2012($0.15)($0.08)ViewN/AView Earnings Details
11/5/2012Q312($0.14)($0.09)$1.89 million$2.15 millionViewN/AView Earnings Details
7/30/2012Q2 2012($0.15)($0.13)ViewN/AView Earnings Details
5/11/2012Q1 2012($0.09)($0.04)ViewN/AView Earnings Details
3/9/2012Q4 2011$0.11$0.15ViewN/AView Earnings Details
11/4/2011Q3 2011$0.10$0.12ViewN/AView Earnings Details
8/5/2011Q2 2011$0.12$0.11ViewN/AView Earnings Details
5/9/2011Q1 2011$0.11$0.12ViewN/AView Earnings Details
3/7/2011Q4 2010$0.09$0.13ViewN/AView Earnings Details
11/5/2010Q3 2010$0.04$0.14ViewN/AView Earnings Details
8/6/2010Q2 2010$0.01$0.05ViewN/AView Earnings Details
5/7/2010Q1 2010($0.01)$0.07ViewN/AView Earnings Details
2/24/2010Q4 2009$0.23($0.01)ViewN/AView Earnings Details
11/4/2009Q3 2009$0.06($0.21)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.14)($0.26)ViewN/AView Earnings Details
5/7/2009Q1 2009$0.02($0.24)ViewN/AView Earnings Details
2/27/2009Q4 2008$3.12($0.37)ViewN/AView Earnings Details
11/4/2008Q3 2008$0.42($0.63)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.49)($0.58)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.42)($0.60)ViewN/AView Earnings Details
2/28/2008Q4 2007($0.33)($0.56)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Osiris Therapeutics (OTCMKTS:OSIR) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Osiris Therapeutics (OTCMKTS:OSIR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/17/2015special$0.209/14/20159/16/20159/30/2015
9/17/2015special$0.2010/14/201510/16/201510/30/2015
(Data available from 1/1/2013 forward)

Insider Trades

Osiris Therapeutics (OTCMKTS OSIR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 44.60%
Institutional Ownership Percentage: 0.27%
Insider Trades by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)
Institutional Ownership by Quarter for Osiris Therapeutics (OTCMKTS:OSIR)

Osiris Therapeutics (OTCMKTS OSIR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/27/2014Matthew Paul NeumayerInsiderSell3,750$16.10$60,375.00View SEC Filing  
5/21/2014Philip Jacoby, Jr.CFOSell15,947$15.43$246,062.2112,500View SEC Filing  
3/14/2014Michelle Leroux WilliamsInsiderSell61,934$14.09$872,650.06View SEC Filing  
11/25/2013Philip Jacoby, Jr.CFOSell18,372$15.99$293,768.2812,500View SEC Filing  
11/15/2013Michelle Leroux WilliamsInsiderSell24,500$15.50$379,750.00View SEC Filing  
8/20/2013Matthew Paul NeumayerInsiderSell11,375$19.75$224,656.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Osiris Therapeutics (OTCMKTS OSIR) News Headlines

Source:

SEC Filings

Osiris Therapeutics (OTCMKTS:OSIR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Osiris Therapeutics (OTCMKTS:OSIR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Osiris Therapeutics (OTCMKTS OSIR) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.